Ferdinando Riccardi: Influence Statistics

Ferdinando Riccardi

Ferdinando Riccardi

Cesare Gridelli and Paolo Maione, Azienda Ospedaliera (AO) San Giuseppe Moscati, Avellino; Alessandro Morabito, Raffaele Costanzo, Gaetano Rocco, Gennaro Daniele, Maria ...

Ferdinando Riccardi: Expert Impact

Concepts for which Ferdinando Riccardi has direct influence: Life cisplatin , Advanced nsclc , Cell lung , Experimental arm , Unselected patients , Firstline erlotinib , Miles3 miles4 .

Ferdinando Riccardi: KOL impact

Concepts related to the work of other authors for which for which Ferdinando Riccardi has influence: Cell lung , Egfr mutations , Acquired resistance , Kinase inhibitors , Nsclc patients , Epidermal growth , Carcinoma small .

KOL Resume for Ferdinando Riccardi

Year
2018

Cesare Gridelli and Paolo Maione, Azienda Ospedaliera (AO) San Giuseppe Moscati, Avellino; Alessandro Morabito, Raffaele Costanzo, Gaetano Rocco, Gennaro Daniele, Maria Carmela Piccirillo, and Francesco Perrone, Istituto Nazionale Tumori, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) -Fondazione G. Pascale; Fortunato Ciardiello, Simona Signoriello and Ciro Gallo, Università degli Studi della Campania Luigi Vanvitelli; Roberto Bianco, Università degli Studi di Napoli Federico II; Ferdinando Riccardi, Azienda Ospedaliera di Rilievo Nazionale Cardarelli, Naples; Luigi Cavanna, Ospedale di Piacenza, Piacenza; Andrea Luciani, Ospedale S. Paolo; Virginio Filipazzi, Ospedale L. Sacco, Polo Universitario, Milan; Andrea Luciani and Silvana Leo, Gruppo Italiano di Oncologia Geriatrica; Manlio Mencoboni, Ospedale Villa Scassi, Azienda Sanitaria Locale 3 Genovese, Genoa; Laura Bonanno, Istituto Oncologico Veneto, IRCCS, Padova; Silvana Leo, AO Vito Fazzi, Lecce; Saverio Cinieri, Ospedale Senatore Antonio Perrino, Brindisi; Marco Angelo Burgio, Istituto Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Meldola; Domenico Bilancia, AO San Carlo, Potenza; Diego Cortinovis, Ospedale San Gerardo, Monza; Francesco Rosetti, Mirano Unità Locale Socio Sanitaria 3, Serenissima Regione Veneto, Mirano; Vittorio Gebbia, Casa di Cura La Maddalena Università di Palermo, Palermo; Fabrizio Artioli, Ospedale Ramazzini di Carpi e Ospedale di Mirandola, Carpi; Roberto Bordonaro, AO Garibaldi Nesima, Catania; Vittorio Fregoni, Istituti Clinici Scientifici Maugeri, Pavia; Fabrizio Nelli, Ospedale Belcolle, Viterbo; and Giuditta di Isernia, Ospedale S. Giovanni Calibita Fatebenefratelli, Rome, Italy.

2012

Author affiliations appear at the end of this article.

Prominent publications by Ferdinando Riccardi

KOL-Index: 9575 . Purpose To test the efficacy of adding cisplatin to first-line treatment for elderly patients with advanced non-small-cell lung cancer (NSCLC) within a combined analysis of two parallel phase III trials, MILES-3 and MILES-4. Patients and Methods Patients with advanced NSCLC who were older than age 70 years with Eastern Cooperative Oncology Group performance status 0 to 1 were randomly ...
Known for Elderly Patients | Cell Lung | Joint Analysis | Life Cisplatin
KOL-Index: 8628 . PURPOSE: Erlotinib prolonged survival of unselected patients with advanced non-small-cell lung cancer (NSCLC) who were not eligible for further chemotherapy, and two phase II studies suggested it might be an alternative to first-line chemotherapy. A randomized phase III trial was designed to test whether first-line erlotinib followed at progression by cisplatin-gemcitabine was not inferior ...
Known for Cell Lung | Experimental Arm | Unselected Patients | Firstline Erlotinib

Key People For Life Cisplatin

Top KOLs in the world
#1
Stein Kaasa
advanced cancer chronic pain quality life
#2
David Osoba†
quality life national cancer institute lung cancer
#3
Marianne Carol Klee
sexual function cervical cancer advanced stages
#4
Bengt Bergman
lung cancer small cell quality life
#5
Sam Hjelmeland Ahmedzai
cancer pain multiple myeloma older people
#6
Neil K Aaronson
breast cancer quality life physical exercise

Cesare Gridelli and Paolo Maione, Azienda Ospedaliera (AO) San Giuseppe Moscati, Avellino; Alessandro Morabito, Raffaele Costanzo, Gaetano Rocco, Gennaro Daniele, Maria Carmela Piccirillo, and Francesco Perrone, Istituto Nazionale Tumori, Istituto di